You are viewing a version of a model that has been updated. To access the latest version, and a more detailed display please go here.

DDMODEL00000114: Russu_2009_dose_escalation_Emax_model

  public model
Short description:
Population approaches to the analysis of dose escalation studies: Emax model
PharmML (0.6.1)
  • Dose escalation studies: a comparison among Bayesian models
  • Russu A., De Nicolao G, Poggesi I, Gomeni R.
  • PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe, 6/2009, Volume 10, pages: 1610
  • (1) Department of Computer Engineering and Systems Science, University of Pavia, Pavia, Italy; (2) GlaxoSmithKline, Clinical Pharmacology/Modelling & Simulation, Verona, Italy
  • Objectives: To apply alternative Bayesian models for the population analysis of the dose-exposure relationship in dose escalation Phase I studies. In these studies, subjects receive increasing dose levels and, at each dose escalation, a decision is made on the next dose level to be administered, based on safety/tolerability constraints. In recent years there has been a growing interest in Bayesian methods applied to such experiments [1,2,3]. In the present work, the performance of four alternative Bayesian models was evaluated on real and simulated datasets and a model comparison procedure was developed for the identification of the most appropriate model. Methods: The dose-exposure relationship was explored using a log-linear model (i.e. a linear model in log-log scale), a power model, an Emax model, and a nonparametric model based on population smoothing splines [4]. In all cases, a Bayesian population approach was adopted. The parametric models were estimated using WinBUGS 1.4.3. Sum of squared residuals, predictive root mean square error, AIC and BIC were used as model comparison criteria. Results: Ten phase I dose escalation studies and 60 simulated datasets (generated with the three parametric models) were analyzed. In the experimental datasets, the power and log-linear models provided comparable results in terms of point estimates and credibility intervals, whereas the Emax model proved inadequate when data showed upward curvature. The population spline approach provided good results for both experimental and simulated datasets. In the former case, the goodness of fit was comparable to parametric models. In the simulated benchmark, population splines performed comparably to the true models used to generate the data. The proposed comparison approach correctly identified the true parametric model in most cases. Conclusions: A thorough model comparison procedure was developed, based on model complexity criteria and crossvalidatory techniques. Applying several criteria represents a useful cross-check when one is faced with the problem of finding the most adequate model. It has been shown that the parallel estimation of four models (three parametric, one nonparametric), complemented with model comparison criteria, can robustly handle a variety of dose-exposure relationships overcoming possible misspecification problems. Moreover, population splines may represent an appealing first-try, especially in early escalation stages, when there is not enough information to support a specific parametric model.
Paolo Magni
Annotations are correct.
This model is not certified.
  • Model owner: Paolo Magni
  • Submitted: Dec 13, 2015 10:44:47 PM
  • Last Modified: Oct 13, 2016 7:05:32 PM
  • Version: 10 public model Download this version
    • Submitted on: Oct 13, 2016 7:05:32 PM
    • Submitted by: Paolo Magni
    • With comment: Edited model metadata online.
  • Version: 7 public model Download this version
    • Submitted on: Jul 16, 2016 3:59:51 PM
    • Submitted by: Paolo Magni
    • With comment: Updated model annotations.
  • Version: 4 public model Download this version
    • Submitted on: Dec 13, 2015 10:44:47 PM
    • Submitted by: Paolo Magni
    • With comment: Edited model metadata online.